Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
about
Progress in treatment of ANCA-associated vasculitisLupus nephritis: current updateCurrent and emerging treatment options in the management of lupusB cells with regulatory properties in transplantation toleranceKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsCellular targeting in autoimmunityRegulatory B cells: an exciting target for future therapeutics in transplantationOcrelizumab: a step forward in the evolution of B-cell therapyPediatric lupus nephritis: Management updateEfficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyA novel epitope from CD22 regulates Th1 and Th17 cell function in systemic lupus erythematosusThe potential utility of B cell-directed biologic therapy in autoimmune diseases.Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases.Antibodies to watch in 2010Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signalingEpitope mapping and key amino acid identification of anti-CD22 immunotoxin CAT-8015 using hybrid β-lactamase displayTargeting B cells with biologics in systemic lupus erythematosus.BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Treatment of systemic lupus erythematosus with epratuzumab.Murine models of systemic lupus erythematosusEpratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.Renal involvement in autoimmune connective tissue diseases.In-/off-label use of biologic therapy in systemic lupus erythematosus.Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II studyTreating Sjögren's Syndrome: Insights for the ClinicianMetabolic regulation of organelle homeostasis in lupus T cellsNotes on the kidney and its diseases for the neurologist.Developments in lupus 2006Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Contemporary treatment of systemic lupus erythematosus: an update for clinicians.Belimumab in systemic lupus erythematosus: an update for clinicians.Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.Epratuzumab in the therapy of oncological and immunological diseases.B lymphocytes as therapeutic targets in systemic lupus erythematosus.Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases.B cell modulation in rheumatology
P2860
Q21195258-601C03B5-F4BC-45E7-9CC7-AFF214C856D0Q22000837-A259E5CE-2D50-4444-B7AF-24683884A835Q26741266-13A72CA3-BE6C-483F-91B3-6DE41311F3EBQ26771404-C335BA60-E744-4CB4-BF28-0A9420962892Q26775756-AB920323-BDE0-4618-9835-2B40969E6F6EQ26824580-69EB9B29-9E82-4610-A32A-ACA98CC3A6A6Q27015093-1C3C41BA-F3B5-427A-899B-893355953C55Q28245986-9AC78886-8AAF-4289-9249-83B2915C02CAQ28660110-53DC3858-A3FB-4B74-B9D7-DF7F95F28090Q28660706-C14442C3-5CD8-4AB8-B802-B794A325AC91Q31118181-EBDD16AE-3591-4044-ABE6-22C9AEC63F59Q33377109-7E6235DB-73A1-4B93-9BB3-C09382564A02Q33385389-C8E92654-3E10-4231-BBBA-604C0E70A1FAQ33542751-DD88EEB2-261E-4AEA-9124-3C538E5A3FD2Q33586280-FE887CFE-2D3F-4496-9B85-8865FAA810D6Q33688243-B87909A2-0507-4822-BB7C-44E33DBEF730Q33691812-0F9E71FB-76F7-4BF3-B4CE-0508385DD242Q33772436-5F25BD46-7264-41C2-9EC7-5A83C2A206D1Q34232326-C9E893B8-980F-4045-9CD3-215FC869746CQ34245983-DA8381A8-4954-4ED1-A99E-7920EABDA60BQ34580559-CA38C82D-1F0E-40B8-9A68-235A53DAFC60Q34591019-1C92B2FD-07CF-456E-8964-2CE9691A1DC6Q34613920-0E33327E-C6DF-41B2-B947-2B62040CAC4DQ34654954-4C8D66E7-3BAB-46BD-8A44-F80AD1B7E91CQ35094536-DF141925-DA90-445E-92B3-B2A767D28BE9Q35170984-3C46ACEF-0F1F-4121-A91B-2F7830906B1EQ35456519-6B6366E1-0798-47CD-8935-B24412FFDB31Q35605535-460693BA-87FD-4A52-8582-22E9E69A242BQ36056942-B345DAEE-2C9B-4D9A-9A9C-1F487D24F864Q36177195-C413AA72-AD55-4184-8ACF-BAC183996299Q36227382-29BF8564-B9DA-4917-9D19-12B34E27CBB0Q36392336-55C63DE2-C38C-459E-9AAD-2E4FD33563F1Q36430066-B31E5BB3-79F9-46A3-8D24-7A8B1015E24CQ36443689-919E7811-369E-45E2-955C-90E358BCD1AAQ36443781-E838EFC2-C1B7-4B40-A70A-537C473121CDQ36569755-FD8279DE-EA75-4419-B848-3A62D4AC67C3Q36636619-4FF75F3F-156F-40A7-B800-F6EA2EFAD4D7Q36653646-87FD9345-C0C6-4FBE-9F78-E03404B6CB8EQ36810295-82496D0C-185B-4B06-AB44-EFB7AC2E159EQ36878215-869D7100-F516-4ECA-9BB8-F9E683A90C99
P2860
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Initial clinical trial of epra ...... f systemic lupus erythematosus
@ast
Initial clinical trial of epra ...... f systemic lupus erythematosus
@en
Initial clinical trial of epratuzumab
@nl
type
label
Initial clinical trial of epra ...... f systemic lupus erythematosus
@ast
Initial clinical trial of epra ...... f systemic lupus erythematosus
@en
Initial clinical trial of epratuzumab
@nl
prefLabel
Initial clinical trial of epra ...... f systemic lupus erythematosus
@ast
Initial clinical trial of epra ...... f systemic lupus erythematosus
@en
Initial clinical trial of epratuzumab
@nl
P2093
P2860
P356
P1476
Initial clinical trial of epra ...... f systemic lupus erythematosus
@en
P2093
David M Goldenberg
Joerg Kaufmann
Thomas Dörner
William A Wegener
P2860
P2888
P356
10.1186/AR1942
P577
2006-04-21T00:00:00Z
P5875
P6179
1040542747